Form 4: STERIS CFO Karen Burton Reports Equity Transactions

STERIS plc CFO Karen L. Burton acquired 5,325 ordinary shares and 18,564 stock options in a routine equity compensation filing.

Summary

• CFO Karen L. Burton acquired 5,325 ordinary shares on June 2, 2026.
• The reporting person disposed of 66 shares to satisfy tax withholding obligations related to the vesting of restricted shares.
• The reporting person was granted 18,564 employee stock options with an exercise price of $230.74.
• Following these transactions, the reporting person holds 13,464 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard executive compensation activity rather than a strategic shift or market-moving event.

Positives

• The acquisition of equity by the CFO aligns management interests with those of shareholders.
• The transaction reflects standard long-term incentive compensation vesting and grant cycles.

Negatives

• None identified; this is a standard regulatory disclosure of executive compensation.

Risks

• The value of the granted stock options is subject to future market performance of STERIS ordinary shares.
• Vesting of restricted shares is subject to continued employment and time-based conditions.

Future Outlook

The filing outlines a multi-year vesting schedule for restricted shares through June 2029 and stock options through June 2030, indicating long-term retention planning.

Management Comments

• No direct management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation typical for large-cap medical device companies, reflecting standard corporate governance practices regarding insider equity holdings.

Comparison to Industry Standards

• The equity grant structure is consistent with standard executive compensation packages at peer medical technology firms.
• Tax withholding practices align with standard SEC and IRS compliance requirements for equity-based compensation.

Stakeholder Impact

• Shareholders should view this as standard alignment of executive incentives with long-term company performance.

Next Steps

• Vesting of 651 restricted shares on June 3, 2026.
• Vesting of 306 restricted shares on June 4, 2026.

Key Dates

Keywords

STERIS, STE, Form 4, Insider Trading, Executive Compensation, CFO, Stock Options